Advancing ADCs: From concept to commercialization

This Lonza white paper explains how ADC development has evolved and how end-to-end technologies and manufacturing capabilities can help accelerate ADCs from concept to commercialization. It highlights payload-linker options, advanced conjugation technologies, scalable manufacturing, and integrated drug product services designed to shorten development timelines and support clinical and commercial production.

• Payload-linker options: Lonza offers proprietary, off-the-shelf, and customized payload-linker solutions for different ADC requirements.
• Fast-track ADC development: The Ibex ® Design ADC program aims to achieve a timeline of 15 months from DNA to IND, with drug substance available for toxicity studies in about 8 months.
• Advanced conjugation: GlycoConnect ® enables site-specific conjugation, supported by Hydraspace ® and toxSYN ® technologies.
• End-to-end manufacturing: Lonza provides integrated drug substance and drug product development, from preclinical and clinical manufacturing through commercial production, with scalable facilities.